Comments
Dr Reddy’s announced on Saturday that following the launch of its generic Buprenorphine and Naloxone Sublingual Film in the US, the District Court of New Jersey has received and reviewed an emergency application from the plaintiffs in the current patent litigation for a temporary restraining order and preliminary injunction against Dr Reddy’s.
Pending a hearing and decision on the injunction application, the court has issued a temporary restraining order against Dr Reddy’s with respect to further sales and commercialisation of Buprenorphine and Naloxone Sublingual Film within the US. The court order does not include a prohibition on commercial manufacturing of the product.
The plaintiffs will be required to post a bond or other security totalling $18 million to satisfy any losses or damages incurred by Dr Reddy’s during the period of the temporary restraining order. The court has scheduled an expedited hearing of the preliminary injunction for Thursday, June 28, and a ruling is expected soon thereafter.
The proceeding only involves one patent, US Patent No. 9,931,305. Dr Reddy’s in a statement said it remains confident about its legal position on this patent and believes it will prevail on the issues raised with respect to the application for injunction.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.